Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancer

Cancer Research

Volumn 72, Issue 15, 2012, Pages 3744-3752

  Webb, Tonya J ^a,e   Li, Xiangming ^c   Giuntoli II, Robert L ^b   Lopez, Pablo H H ^a   Heuser, Christoph ^d   Schnaar, Ronald L ^a   Tsuji, Moriya ^c   Kurts, Christian ^d   Oelke, Mathias ^a   Schneck, Jonathan P ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

^d UNIVERSITY OF BONN   (Germany)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD1D ANTIGEN; GANGLIOSIDE GD3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY COMBINING SITE; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNE EVASION; INNATE IMMUNITY; LIPID ANALYSIS; LYMPHOCYTE ACTIVATION; MOUSE; NATURAL KILLER T CELL; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; TUMOR ESCAPE;

ANIMALS; ANTIGENS, CD1D; ASCITES; CARCINOMA; CELLS, CULTURED; DOWN-REGULATION; FEMALE; GANGLIOSIDES; HUMANS; IMMUNITY, INNATE; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; OVARIAN NEOPLASMS; TUMOR ESCAPE;

EID: 84864842768     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2695     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Santin AD, Ravindranath MH, Bellone S, Muthugounder S, Palmieri M, O'Brien TJ, et al. Increased levels of gangliosides in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG 2004;111:613-8.
3. Valentino L, Moss T, Olson E, Wang HJ, Elashoff R, Ladisch S. Shed tumor gangliosides and progression of human neuroblastoma. Blood 1990;75:1564-7.
4. Santin AD, Bellone S, Ravaggi A, Pecorelli S, Cannon MJ, Parham GP. Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. Obstet Gynecol 2000;96:422-30.
5. Ramakrishna V, Ross MM, Petersson M, Gatlin CC, Lyons CE, Miller CL, et al. Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. Int Immunol 2003;15:751-63.
6. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13.
7. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
8. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005;102:18538-43.
9. Sriram V, Cho S, Li P, O'Donnell PW, Dunn C, Hayakawa K, et al. Inhibition of glycolipid shedding rescues recognition of a CD1+ T cell lymphoma by natural killer T (NKT) cells. Proc Natl Acad Sci U S A 2002;99:8197-202.
10. Brutkiewicz RR, Bennink JR, Yewdell JW, Bendelac A. TAP-independent, β2-microglobulin-dependent surface expression of functional mouse CD1.1. J Exp Med 1995;182:1913-9.
11. Lantz O, Bendelac A. An invariant T cell receptor a chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans. J Exp Med 1994;180:1097-106.
12. Burdin N, Brossay L, Koezuka Y, Smiley ST, Grusby MJ, Gui M, et al. Selective ability of mouse CD1 to present glycolipids: α- galactosylceramide specifically stimulates Vα14+ NK T lymphocytes. J Immunol 1998;161:3271-81.
13. Kinjo Y, Wu D, KimG, Xing GW, Poles MA, Ho DD, et al. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 2005;434:520-5.
14. Watarai H, Nakagawa R, Omori-Miyake M, Dashtsoodol N, Taniguchi M. Methods for detection, isolation and culture of mouse and human invariant NKT cells. Nat Protoc 2008;3:70-8.
15. Molling JW, Moreno M, van der Vliet HJ, von Blomberg BM, van den Eertwegh AJ, Scheper RJ, et al. Generation and sustained expansion of mouse spleen invariant NKT cell lines with preserved cytokine releasing capacity. J Immunol Methods 2007;322:70-81.
16. Webb TJ, Bieler JG, Schneck JP, Oelke M. Ex vivo induction and expansion of natural killer T cells by CD1d1-Ig coated artificial antigen presenting cells. J Immunol Methods 2009;346:38-44.
17. Webb TJ, Giuntoli RL II, Rogers O, Schneck J, Oelke M. Ascites specific inhibition of CD1d-mediated activation of natural killer T cells. Clin Cancer Res 2008;14:7652-8.
18. Schnaar RL, Needham LK. Thin-layer chromatography of glycosphingolipids. Methods Enzymol 1994;230:371-89.
19. Schmieg J, Yang G, Franck RW, Tsuji M. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-galactosylceramide. J Exp Med 2003;198:1631-41.
20. Shiratsuchi T, Schneck J, Kawamura A, Tsuji M. Human CD1 dimeric proteins as indispensable tools for research on CD1-binding lipids and CD1-restricted T cells. J Immunol Methods 2009;345:49-59.
21. Tupin E, Kronenberg M. Activation of natural killer T cells by glycolipids. Methods Enzymol 2006;417:185-201.
22. Svennerholm L. Designation and schematic structure of gangliosides and allied glycosphingolipids. Prog Brain Res 1994;101:XI-XIV.
23. Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Marth JD, et al. Symbol nomenclature for glycan representation. Proteomics 2009;9:5398-9.
24. Park JE, Wu DY, Prendes M, Lu SX, Ragupathi G, Schrantz N, et al. Fine specificity of natural killer T cells against GD3 ganglioside and identification of GM3 as an inhibitory natural killer T-cell ligand. Immunology 2008;123:145-55.
25. Wu DY, Segal NH, Sidobre S, Kronenberg M, Chapman PB. Cross-presentation of disialoganglioside GD3 to natural killer T cells. J Exp Med 2003;198:173-81.
26. Wu D, Zajonc DM, Fujio M, Sullivan BA, Kinjo Y, Kronenberg M, et al. Design of natural killer T cell activators: structure and function of a microbial glycosphingolipid bound to mouse CD1d. Proc Natl Acad Sci U S A 2006;103:3972-7.
27. Sriram V, Du W, Gervay-Hague J, Brutkiewicz RR. Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells. Eur J Immunol 2005;35:1692-701.
28. Portoukalian J, David MJ, Shen X, Richard M, Dubreuil C. Tumor size-dependent elevations of serum gangliosides in patients with head and neck carcinomas. Biochem Int 1989;18:759-65.
29. Ravindranath MH, Tsuchida T, Morton DL, Irie RF. Ganglioside GM3:GD3 ratio as an index for the management of melanoma. Cancer 1991;67:3029-35.
30. Nasi ML, Meyers M, Livingston PO, Houghton AN, Chapman PB. Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside. Melanoma Res 1997;7 Suppl 2:S155-62.
31. Forero A, Shah J, Carlisle R, Triozzi PL, LoBuglio AF, Wang WQ, et al. A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma. Cancer Biother Radiopharm 2006;21:561-8.
32. Giaccone G, Debruyne C, Felip E, Chapman PB, Grant SC, Millward M, et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol 2005;23:6854-64.
33. Lo AS, Ma Q, Liu DL, Junghans RP. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors. Clin Cancer Res 2010;16:2769-80.